The fibrinolysis system is responsible for removing blood clots. Hyperfibrinolysis describes a situation with markedly enhanced fibrinolytic activity, resulting in increased, sometimes catastrophic bleeding. Hyperfibrinolysis can be caused by acquired or congenital reasons. Among the congenital conditions for hyperfibrinolysis, deficiency of alpha 2 antiplasmin ref Carpenter SL, Mathew P. Alpha 2 antiplasmin and its deficiency fibrinolysis out of balance. Haemophilia, 2008 14 1250 4 ref alpha 2 plasmin inhibitor or plasminogen activator inhibitor type 1 PAI 1 ref Takahashi Y, Tanaka T, Minowa H et al. Hereditary partial deficiency of plasminogen activator inhibitor 1 associated with a lifelong bleeding tendency. Int J Hematol 1996 64 61 8 ref are very rare. The affected individuals show a hemophilia like bleeding phenotype. Acquired hyperfibrinolysis is found in liver disease , ref Goerlinger K. Coagulation management during liver transplantation. Haemostaseologie 2006 26 3 Suppl 1 S64 76 ref in patients with severe Physical trauma trauma , ref Levrat A, Gros A, Rugeri L, Inaba K, Floccard B, Negrier C, David JS. Evaluation of rotation thrombelastography for the diagnosis of hyperfibrinolysis ..., hyperfibrinolysis is associated with poor outcome. ref Sch chl H. Hyperfibrinolysis a prognostic ... polymerization and inhibit platelet aggregation. Moreover, plasmin which is formed in excess in hyperfibrinolysis ... and clot stability, may be a major cause for clinical bleeding. Diagnosis The diagnosis of hyperfibrinolysis ... time or thrombin time are not very sensitive for hyperfibrinolysis, and influenced by numerous ... hyperfibrinolysis very sensitively in a functional approach. The APTEM test, a tissue factor activated ... hyperfibrinolysis by comparing the TEM result of this assay with the EXTEM test same activator ... hyperfibrinolysis. ref Vorweg M, Hartmann B, Kn ttgen D, Jahn MC, Doehn M. Management of fulminant ..., the treatment or prophylaxis of hyperfibrinolysis is made with synthetic drugs such as tranexamic ... more details
, a more rapid detection of fibrinolytic activity, especially hyperfibrinolysis, is possible ... Levrat et al. Evaluation of rotation thrombelastography for the diagnosis of hyperfibrinolysis in trauma ... states. However, acquired disturbance of fibrinolysis Hyperfibrinolysis , is not uncommon. Many trauma patients suffer from an overwhelming activation of tissue factor and thus massive hyperfibrinolysis ... patient. World J Surg 2007 31 1055 64 ref Also in other disease states hyperfibrinolysis may ... as inhibitors of fibrinolysis. Their application may be beneficial in patients with hyperfibrinolysis ... more details
time point or when the test has been stopped. A low LI X value or a high ML value indicates hyperfibrinolysis ... rapid loss of clot stability by hyperfibrinolysis may lead to bleeding complications which can be treated ... to EXTEM allows to detect fulminant hyperfibrinolysis. Therefore the test helps in identifying the necessity ... more details
PBB geneid 5327 Tissue plasminogen activator abbreviated tPA or PLAT is a protein involved in the breakdown of blood clot s. It is a serine protease EC number 3.4.21.68 found on endothelial cell s, the cells that line the blood vessel s. As an enzyme , it catalysis catalyzes the conversion of plasminogen to plasmin , the major enzyme responsible for clot breakdown. Because it works on the clotting system , tPA is used in clinical medicine to treat embolic or thrombotic stroke . Use is contraindicated in hemorrhagic stroke and head trauma. tPA may be manufactured using Recombinant DNA recombinant Biotechnology Pharmaceutical products biotechnology techniques. tPA created this way may be referred to as recombinant tissue plasminogen activator rtPA . Function Image Fibrinolysis.png left thumb 250px A simplified illustration demonstrates clot breakdown fibrinolysis , with blue arrows denoting stimulation, and red arrows inhibition. tPA and plasmin are the key enzymes of the fibrinolytic pathway in which tPA mediated plasmin generation occurs. To be specific, tPA cleaves the zymogen, plasminogen at its Arg560 Val561 peptide bond, into the serine protease plasmin. Increased enzymatic activity causes hyperfibrinolysis , which manifests as excessive bleeding. Decreased activity leads to hypofibrinolysis which can result in thrombosis or embolism . Tissue plasminogen activator also plays a role in cell migration and tissue remodeling . Genetics Tissue plasminogen activator is a protein encoded by the PLAT gene , which is located on chromosome 8 . The primary transcript produced by this gene undergoes alternative splicing , producing three distinct messenger RNA s. Clinical applications tPA is used in diseases that feature blood clot s, such as pulmonary embolism , myocardial infarction , and stroke , in a medical treatment called thrombolysis . To be most effective in ischemic stroke, tPA must be administered as early as possible after the onset of symptoms. Protocol guideli ... more details
Encyclopedia
top
